or Try an Advanced Search...

    Technical Analysis for ANVS - Annovis Bio, Inc.

    Grade Last Price % Change Price Change
    F 6.86 4.89% 0.32
    ANVS closed down 2.1 percent on Wednesday, November 20, 2024, on 1.15 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical ANVS trend table...
    Date Alert Name Type % Chg
    New Downtrend Bearish 4.89%
    Wide Bands Range Expansion 4.89%
    Down 3 Days in a Row Weakness 4.89%
    Down 4 Days in a Row Weakness 4.89%
    Down 5 Days in a Row Weakness 4.89%
    Oversold Stochastic Weakness 4.89%
    NR7 Range Contraction 2.69%
    NR7-2 Range Contraction 2.69%
    Narrow Range Bar Range Contraction 2.69%
    Wide Bands Range Expansion 2.69%
    Older End-of-Day Signals for ANVS ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High 10 minutes ago
    Outside Day 10 minutes ago
    Up 5% 10 minutes ago
    Up 3% about 1 hour ago
    Up 2% about 2 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ANVS Chart by TradingView
    Basic chart:

    Profile

    Annovis Bio, Inc. develops drugs for Alzheimer's and Parkinson's diseases and other neurodegenerative disorders. It offers posiphen compound for mild cognitive impairment and early stage Alzheimer's disease and bisnorcymserine compound that inhibits amyloid formation and prevents the progression of the Alzheimer's disease. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Organ Systems Alzheimer's Disease Parkinson's Disease Psychiatric Diagnosis Amyloid Nervous System Neurodegeneration Neurodegenerative Disorders Cognitive Disorders Cognitive Impairment Learning Disabilities Neuroprotection Early Stage Alzheimer's Disease Gladstone Institutes

    Is ANVS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 12 Annovis Invited to Present at National Institute on Aging Workshop on Dementia with Lewy Bodies (DLB)
    Nov 11 Annovis Bio GAAP EPS of -$0.97 misses by $0.58
    Nov 11 Annovis Bio Reports Third Quarter Financial Results and Provides Business Update
    Nov 11 Will Annovis Bio (NYSE:ANVS) Spend Its Cash Wisely?
    Nov 7 Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist
    Oct 31 IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio
    Oct 22 Annovis to Highlight Buntanetap's Alzheimer's Research Progress with Presentations at CTAD 2024
    Oct 17 Annovis Bio: Funding May Be An Issue For Announced Phase 3 Trials
    Oct 17 Annovis Bio To Continue Alzheimer's Disease Clinical Trials
    Oct 17 Annovis Bio Shows Promise on FDA Clearance for Alzheimer's Drug
    See more ANVS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 22.49
    52 Week Low 4.53
    Average Volume 252,137
    200-Day Moving Average 8.91
    50-Day Moving Average 8.33
    20-Day Moving Average 8.26
    10-Day Moving Average 7.32
    Average True Range 0.57
    RSI (14) 28.57
    ADX 26.32
    +DI 11.49
    -DI 31.90
    Chandelier Exit (Long, 3 ATRs) 8.83
    Chandelier Exit (Short, 3 ATRs) 8.14
    Upper Bollinger Bands 10.46
    Lower Bollinger Band 6.06
    Percent B (%b) 0.11
    BandWidth 53.30
    MACD Line -0.56
    MACD Signal Line -0.33
    MACD Histogram -0.2303
    Fundamentals Value
    Market Cap 69.19 Million
    Num Shares 10.6 Million
    EPS -4.84
    Price-to-Earnings (P/E) Ratio -1.35
    Price-to-Sales 0.00
    Price-to-Book 17.40
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 7.16
    Resistance 3 (R3) 7.19 7.01 7.05
    Resistance 2 (R2) 7.01 6.86 7.00 7.02
    Resistance 1 (R1) 6.78 6.76 6.69 6.75 6.98
    Pivot Point 6.60 6.60 6.56 6.59 6.60
    Support 1 (S1) 6.37 6.45 6.28 6.34 6.10
    Support 2 (S2) 6.19 6.35 6.18 6.06
    Support 3 (S3) 5.96 6.19 6.03
    Support 4 (S4) 5.93